PT
PTCT
PTCT What PTC Therapeutics promised, and what happened
Guidance
What management said, and what became of it
14 of 15 judged targets kept · 6 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| MSH3 splicing program development candidate election | Elect development candidate in 2026 | Dec 2025 | We recently selected a development candidate for our MSH3 splicing program, PTC303. | Achieved |
| FY2026 product revenue guidance | $700 million to $800 million | Dec 2025 | we are raising our full year 2026 product revenue guidance to $850 million to $950 million and now expect total revenue of $1.18 billion to $1.28 billion | Revised Up |
| Vatiquinone PROVE-FA open-label study initiation | Initiate within the next few months (later specified as the third quarter of 2026) | Mar 2026 | We plan to initiate this study, PROVE-FA, in the third quarter of this year. | On Track |
The full ledger
Open PTC Therapeutics’s full ledger
A free account opens 5 company ledgers a month. All 21 tracked commitments, with each call’s wording and source.
The rest of the ledger
Pro opens all 21 tracked commitments for PTC Therapeutics
Above is what the last two calls moved. Pro adds every quarter's revision, the source quote behind each one, and the topics management has stopped answering.